Amneal Pharmaceuticals (AMRX) EBT (2017 - 2026)

Amneal Pharmaceuticals has reported EBT for 10 years, with the latest figure at $71.0 million in Q2 2026.

• On a quarterly basis, EBT rose 37.28% year-over-year to $71.0 million in Q2 2026; TTM through Jun 2026 was $201.2 million, a 125.28% increase from a year earlier, with the FY2025 full-year figure at $139.2 million, up 353.05% from the prior year.
• EBT was $71.0 million for Q2 2026 at Amneal Pharmaceuticals, down from $80.2 million in the prior quarter.
• The five-year high for EBT was $80.2 million in Q1 2026, with the low at -$232.7 million in Q2 2022.
• Average EBT over 5 years is -$2.9 million, with a median of $8.8 million recorded in 2022.
• The largest YoY upside for EBT was 953.07% in 2023 against a maximum downside of 990.28% in 2023.
• Over 5 years, EBT stood at -$7.7 million in 2022, then tumbled by 990.28% to -$83.5 million in 2023, then surged by 81.65% to -$15.3 million in 2024, then surged by 460.57% to $55.2 million in 2025, then increased by 28.52% to $71.0 million in 2026.
• The last three EBT figures came in at $71.0 million (Q2 2026), $80.2 million (Q1 2026), and $55.2 million (Q4 2025), per Business Quant data.